Emerging trends in pharmaceutical design and drug manufacturing are shifting toward presenting the market with new ways to develop medications. Specialty medications continue to be a major area of pharmaceutical development and have become widely discussed in workers’ comp due to their significant costs. Although they represent approximately 1% of drug utilization, they account for nearly 7% of prescription drug costs and represent the fastest-growing segment of the U.S. pharmaceutical market. While specialty drug products are often associated with a hefty price tag, some can offer clinical advantages when deployed for the right patient at the right time, making careful oversight and patient selection imperative to achieving desired outcomes in this space. Watch the video blog to learn more.
More stories
PDF
News Release
Mitchell Genex Finalizes Coventry Workers’ Comp Services Acquisition
San Diego, CA, and Wayne, PA—Mitchell | Genex, a leading provider of cost containment technology, clinical services, and disabilit
Workers' Comp
News Release
Mitchell | Genex Finalizes Coventry Workers' Comp Services Acquisition
Deal expands industry-leading solutions to boost better claims outcomes and improve lives for injured individuals
Workers' Comp
News Release
Mitchell Genex Finalizes Coventry Workers’ Comp Services Acquisition
San Diego, CA, and Wayne, PA—Mitchell | Genex, a leading provider of cost containment technology, clinical services, and disabilit
Mitchell
Article
Workers’ Comp Data: Healthcare Industry Sector is the Source of the Majority of COVID-19 Claims
Data analysis by Aarthi Thiruvengadam Over the first few months of the COVID-19 pandemic, the workers’ compensation industry has gone thro
Workers' Comp
Article
Therapeutic Alternatives—A Closer Look
Brand name medications are often scrutinized by the workers’ compensation industry for their high cost.
Workers' Comp
Blog
Brand and Generic Medication Trends
Part Two: Evaluating In-Network and Out-of-Network Trends In this final post related to our in-network and out-of-network analysis we